X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
SUN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs842354-   
Low Rs572255-   
Sales per share (Unadj.) Rs131.6105.2-  
Earnings per share (Unadj.) Rs32.7-26.5-  
Cash flow per share (Unadj.) Rs38.0-22.0-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.782.6-  
Shares outstanding (eoy) m2,399.26168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.42.9 185.7%   
Avg P/E ratio x21.6-11.5 -188.3%  
P/CF ratio (eoy) x18.6-13.9 -134.4%  
Price / Book Value ratio x4.63.7 125.6%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,87751,396 3,301.6%   
No. of employees `00017.54.3 408.0%   
Total wages/salary Rs m49,0233,226 1,519.8%   
Avg. sales/employee Rs Th18,028.34,137.7 435.7%   
Avg. wages/employee Rs Th2,798.8751.4 372.5%   
Avg. net profit/employee Rs Th4,479.5-1,042.6 -429.6%   
INCOME DATA
Net Sales Rs m315,78417,763 1,777.7%  
Other income Rs m6,232124 5,009.6%   
Total revenues Rs m322,01617,888 1,800.2%   
Gross profit Rs m100,893-3,078 -3,277.6%  
Depreciation Rs m12,648767 1,649.7%   
Interest Rs m3,998481 830.9%   
Profit before tax Rs m90,479-4,202 -2,153.4%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116263 4,614.7%   
Profit after tax Rs m78,462-4,476 -1,753.0%  
Gross profit margin %31.9-17.3 -184.4%  
Effective tax rate %13.4-6.2 -214.3%   
Net profit margin %24.8-25.2 -98.6%  
BALANCE SHEET DATA
Current assets Rs m329,53713,010 2,532.9%   
Current liabilities Rs m178,8707,320 2,443.6%   
Net working cap to sales %47.732.0 148.9%  
Current ratio x1.81.8 103.7%  
Inventory Days Days79111 71.2%  
Debtors Days Days83124 67.2%  
Net fixed assets Rs m204,7667,584 2,700.1%   
Share capital Rs m2,39982 2,909.2%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,39713,942 2,628.0%   
Long term debt Rs m14,3614,900 293.1%   
Total assets Rs m614,10226,338 2,331.6%  
Interest coverage x23.6-7.7 -305.6%   
Debt to equity ratio x00.4 11.2%  
Sales to assets ratio x0.50.7 76.2%   
Return on assets %13.4-15.2 -88.5%  
Return on equity %21.4-32.1 -66.7%  
Return on capital %24.8-19.8 -125.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,8221,516 4,671.0%  
From Investments Rs m-42,216-466 9,067.9%  
From Financial Activity Rs m-22,8544,447 -514.0%  
Net Cashflow Rs m6,1075,497 111.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.88 Rs / ZAR

Compare SUN PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: STERLING BIOTECH  NOVARTIS  SANOFI INDIA  STRIDES SHASUN LTD  VENUS REMEDIES  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS